Q2 2025 13F Holders as of 30 Jun 2025
-
Type / Class
-
Equity / Common Stock, par value $0.01 per share
-
Shares outstanding
-
29,149,043
-
Total 13F shares
-
18,415,660
-
Share change
-
-201,755
-
Total reported value
-
$139,219,060
-
Put/Call ratio
-
0%
-
Price per share
-
$7.56
-
Number of holders
-
104
-
Value change
-
-$1,129,334
-
Number of buys
-
47
-
Number of sells
-
58
Institutional Holders of ENANTA PHARMACEUTICALS INC - Common Stock, par value $0.01 per share (ENTA) as of Q2 2025
As of 30 Jun 2025,
ENANTA PHARMACEUTICALS INC - Common Stock, par value $0.01 per share (ENTA) was held by
104 institutional
shareholders
that filed Form 13F with the SEC.
Together, they reported ownership of
18,415,660 shares.
The largest 10 holders included
FARALLON CAPITAL MANAGEMENT LLC, Krensavage Asset Management, LLC, VANGUARD GROUP INC, BlackRock, Inc., MILLENNIUM MANAGEMENT LLC, ACADIAN ASSET MANAGEMENT LLC, MARSHALL WACE, LLP, Stonepine Capital Management, LLC, JANUS HENDERSON GROUP PLC, and GEODE CAPITAL MANAGEMENT, LLC.
This page lists
105
institutional shareholders reporting positions in this security
for the Q2 2025 filing period.
| Investor |
Option |
Weight % |
Change % |
Value $ |
* Price
|
Shares |
Share Change |
Activity |
Report Period |
* Reported Price is the price of the security as of the portfolio date. This value is significant in that it is the last known price at which the security was still held.
An asterisk sign (*) next to the price indicates that the price is likely invalid.